Atrasentan in Patients With Proteinuric Glomerular Diseases

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 103 participants.

Also called NCT04573920

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04573920
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Italy, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04573920. Non-randomized; no masking; primary purpose treatment. Start 2021-03-15 (actual); primary completion 2024-07-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atrasentan in Patients With Proteinuric Glomerular Diseases
Acronym
AFFINITY
Condition
IgA Nephropathy
Condition
Focal Segmental Glomerulosclerosis
Condition
Alport Syndrome
Condition
Diabetic Kidney Disease
Condition
Diabetic Nephropathy Type 2
Condition
Immunoglobulin A Nephropathy
Intervention (Drug)
Atrasentan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04573920
Content hash
450080a1fff3a4ffeea4fe71735e1fa04758df3afa8f0f8a5a958b6c70155314